RVMD FY 2022 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$20B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$35M+20.4% YoY

Gross Profit

$35M100.0% margin

Operating Income

-$258M-730.0% margin

Net Income

-$249M-703.0% margin

EPS (Diluted)

$-3.08

Cash Flow

Operating Cash Flow

-$224M

Free Cash Flow

-$235M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$812M

Total Liabilities

$127M

Stockholders' Equity

$685M

Cash & Equivalents

$161M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$35M	$29M	+20.4%
Gross Profit	$35M	$29M	+20.4%
Operating Income	-$258M	-$188M	-37.4%
Net Income	-$249M	-$187M	-32.9%